Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456586 · ClinicalTrials.gov registry record · Phase 2
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
A Phase 2 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00456586 is a Phase 2 study that has completed, run by Kyowa Kirin. The registered enrollment target is 180 participants.
The verdict
NCT00456586, a Phase 2 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.
Interventions
- DRUG KW-6002 (istradefylline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2002-04 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456586
The ClinicalTrials.gov registry entry for NCT00456586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KW-6002 (istradefylline) is the first listed.
NCT00456586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00456586 about?
NCT00456586 is a clinical study titled "12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa". 12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.
What is the current status of trial NCT00456586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2002-04. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00456586?
The interventions under investigation include: KW-6002 (istradefylline) (DRUG).
Who is sponsoring clinical trial NCT00456586?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.